

What is claimed is:

1. A drug delivery system compound which comprises a carboxy(C<sub>1-4</sub>)alkyl-dextran polyalcohol modified with galactose or galactosamine and a residue of drug compound bound to the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol.
2. The drug delivery system compound according to claim 1, wherein the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol modified with galactose or galactosamine and the residue of drug compound are bound to each other by a spacer.
3. The drug delivery system compound according to claim 2, wherein the spacer comprises one amino acid or 2 to 8 amino acids linked by peptide bond(s).
4. The drug delivery system compound according to claim 1, wherein the carboxy(C<sub>1-4</sub>) alkyldextran polyalcohol modified with galactose or galactosamine is formed by binding the galactose or galactosamine and a carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol by a linker.
5. The drug delivery system compound according to claim 4, wherein the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol modified with galactose or galactosamine has a cluster modification by galactose or galactosamine bound by a linker.
6. A drug delivery system compound which is obtainable by binding a residue of a drug compound to a carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol in which a part of carboxyl groups of the carboxy(C<sub>1-4</sub>)alkyl moiety are modified with galactose or galactosamine.
7. The drug delivery system compound according to claim 6, which is obtainable by binding the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol and the residue of drug compound by a spacer.

8. The drug delivery system compound according to claim 6, which is obtainable by binding the residue of drug compound to the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol which is produced by binding the galactose or galactosamine or a linker bound with the galactose or galactosamine to a part of carboxyl groups of the carboxy(C<sub>1-4</sub>)alkyl moiety of the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol.

9. A drug delivery system compound which is obtainable by modifying with galactose or galactosamine a carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol in which a residue of a drug compound is bound to a part of carboxyl groups of the carboxy(C<sub>1-4</sub>)alkyl moiety by a spacer.

10. The drug delivery system compound according to claim 9, which is obtainable by binding the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol and the galactose or galactosamine by a linker.

11. The drug delivery system compound according to claim 9, which is obtainable by modifying with galactose or galactosamine a carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol produced by binding a residue of drug compound to a part of carboxyl groups of the carboxy (C<sub>1-4</sub>)alkyl moiety of the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol by a spacer comprising one amino acid or a spacer comprising 2 to 8 amino acids linked by peptide bond(s).

12. The drug delivery system compound according to claim 1, wherein substitution degree of galactose or galactosamine, or clustered galactose or galactosamine is 0.01-1.0 per saccharide residue of the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol.

13. The drug delivery system compound according to claim 1, wherein the dextran polyalcohol that constitutes the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol is a dextran polyalcohol which is obtained by treating dextran under conditions that enable substantially complete polyalcoholization.

14. The drug delivery system compound according to claim 1, wherein the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol is carboxymethyldextran polyalcohol.

15. The drug delivery system compound according to claim 1, wherein the drug compound is an antineoplastic agent or an anti-inflammatory agent.

16. The drug delivery system compound according to claim 15, wherein the drug compound is an antineoplastic agent.

17. The drug delivery system compound according to claim 1, wherein the drug compound is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione.

18. The drug delivery system compound according to claim 17, which is a medicament for treating liver cancer.

19. A carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol modified with galactose or galactosamine.

20. A polymer carrier comprising a carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol modified with galactose or galactosamine.